Navigation Links
Creating new life forms that may help eradicate cancer affecting women

Instead of using the usual cancer-fighting modalities, surgery, chemotherapy, or radiation, researchers from a drug development company called Advaxis, have embarked on a novel approach to fighting cancer: Engaging the immune system to attack cancer in the same the way it would a flu vaccine, by creating new life forms.

Dr. Vafa Shahabi, Advaxis' Director of Research and Development, reports that because the human immune system is not designed to fight cancer on its own, she and her colleagues are trying to harness its power through a new kind of life form: specifically a family of vaccines, which they call Lovaxin. The vaccines are comprised of new strains of bacteria created in Advaxis' laboratory that are programmed to kill off specific cancers.

The Key: A Microbe Found in Dairy Products

Central to this startling discovery is the microbe Listeria monocytogenes, a common bacterium found in milk, cheese and other dairy products. This microorganism apparently aids in fighting cancer by activating the body's own killer (cytotoxic T) cells to elicit a stronger than normal immune response to the presence of cancer cells. The vaccines "teach" the immune system to mount a specialized, targeted response that is lethal to cancer.

When Listeria is introduced in the body, it has a powerful, direct stimulatory effect on the activities of tumor-killing T cells. "Essentially the modified Listeria vaccines harness the power of the immune system against this infectious agent," explains Dr. Shabahi, "and then directs it to successfully attack cancer cells. The bacterium in effect then becomes a cancer-fighting 'Trojan horse,' with the enemy tucked inside."

For breast cancer, Dr. Shababi's team fused Listeria with a tumor-associated protein, HER-2/Neu, to immune cells, to create a vaccine called Lovaxin B. What these cells do is enlist killer T cells to seek and destroy tumor cells that over-express the HER-2/Neu molecule. This is significant because HER-2/Neu is over- expressed in 20%- 40% of all breast cancers.

As Dr. Shababi explains: "We not only created a new breast cancer vaccine, but also have a new life form, since the modified Listeria becomes a new strain, not seen in nature. In effect, it becomes a cancer fighting "superbug" capable of treating breast cancer in patients whose tumors express the HER-X/Neu protein." Advaxis has already created several strains for potential use in future vaccines to treat other cancers. The company is also currently testing its cervical cancer vaccine, Lovaxin C, in phase I/II trials.


Source:Advaxis, Inc.

Related biology news :

1. Creating a window on oceans in motion
2. Products containing specific probes for detecting alternative splice forms protected
3. IBM Transforms the Art of Scientific Expeditions
4. MIT researcher presents new view of how the cortex forms
5. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
6. New study explores beetle species with two forms of females
7. How the octopus forms an elbow
8. AIDS-related cognitive impairment exists in two separate forms
9. Scientists discover new life forms in the Arctic Ocean
10. Genetic pathways to curable and incurable forms of pancreatic cancer identified
11. Breast tumors in mice eradicated using cancer vaccine
Post Your Comments:

(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology: